Privately-held California, USA-based biotech Unnatural Product (UNP), which is developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the appointment of Dr Neera Ravindran as chief financial officer (CFO).
Dr Ravindran brings more than 20 years of deep public markets and private company experience, with a demonstrated ability to raise capital, to UNP as the company scales for its next stage of growth. In her role, she will lead UNP’s financial strategy and operations, including capital planning, competitive analysis, and investor relations. In addition, she will support business development and execution of corporate strategy as UNP advances programs from its macrocyclic peptide pipeline across multiple disease areas toward clinical investigation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK